Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Property:RefTags

From GxPlex

Jump to: navigation, search

Text

Raw TAG-ID list for this reference (used for glossary queries).

previous 202050100250500next 20
Showing 20 pages using this property.
U
USA FDA Guidance for Industry - Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring Aug-2013 IV A. Adherence +
TAG-00137-Mon-che ++ TAG-00140-Ris-nRi ++ TAG-00077-Inc-gsk ++ TAG-00033-Pro-oto  +
USA FDA Guidance for Industry - Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring Aug-2013 IV A. Conduct +
TAG-00137-Mon-che ++ TAG-00140-Ris-nRi ++ TAG-00123-Bli-ppe ++ TAG-00145-Ran-ute  +
I
ICH ICH E6 Guideline R3 (2025) III. Annex 1 3.11.4 3.11.4.3 - 3.11.4.6 +
TAG-00137-Mon-che ++ TAG-00144-Qua-gew ++ TAG-00291-Qua-tsk ++ TAG-00329-Saf-lne ++ TAG-00317-Obj-set  +
E
EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 Article 72 Pragraph 2 +
TAG-00137-Mon-che ++ TAG-00245-Spo-ten ++ TAG-00201-Cli-eSt ++ TAG-00329-Saf-lne ++ TAG-00155-Med-Med  +
EU Regulation (EU) 2017/746 - in vitro diagnostic medical devices 20-Mar-2023 Article 68 Paragraph 2 +
TAG-00137-Mon-che ++ TAG-00245-Spo-ten ++ TAG-00231-Per-ung ++ TAG-00329-Saf-lne ++ TAG-00220-Inv-agn  +
EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 Article 48 +
TAG-00137-Mon-che ++ TAG-00245-Spo-ten ++ TAG-00329-Saf-lne ++ TAG-00129-Dat-ali ++ TAG-00008-Cli-ngK  +
U
USA FDA Guidance for Industry - Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring Aug-2013 VI D. +
TAG-00137-Mon-che ++ TAG-00257-Sit-zen ++ TAG-00081-Sit-svi ++ TAG-00017-Spo-die ++ TAG-00201-Cli-eSt  +
USA FDA Guidance for Industry - Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring Aug-2013 III - IV. +
TAG-00137-Mon-che ++ TAG-00293-Cen-sMo ++ TAG-00065-Sou-nüb ++ TAG-00338-Met-odi ++ TAG-00327-Exa-spi  +
USA FDA Guidance for Industry - Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring Aug-2013 IV A. +
TAG-00140-Ris-nRi ++ TAG-00137-Mon-che ++ TAG-00100-Lab-bor ++ TAG-00320-Foo-eri  +
D
DEU KPBV - Klinische Prüfung-Bewertungsverfahren-Verordnung 31-Jan-2022 § 8 +
TAG-00142-Mul-ent ++ TAG-00017-Spo-die ++ TAG-00134-Eth-kom ++ TAG-00008-Cli-ngK ++ TAG-00057-Com-deR  +
W
WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 13 +
TAG-00142-Mul-ent ++ TAG-00133-Ind-rhe ++ TAG-00329-Saf-lne ++ TAG-00341-Res-ben  +
I
ICH ICH E6 Guideline R3 (2025) III. Annex 1 3.9.3 +
TAG-00143-Non-abw ++ TAG-00017-Spo-die ++ TAG-00033-Pro-oto ++ TAG-00129-Dat-ali  +
ICH ICH E6 Guideline R3 (2025) Appendix B 12.3 +
TAG-00143-Non-abw ++ TAG-00033-Pro-oto ++ TAG-00328-Com-egu  +
ICH ICH E6 Guideline R3 (2025) III. Annex 1 3.12 +
TAG-00143-Non-abw ++ TAG-00328-Com-egu ++ TAG-00245-Spo-ten ++ TAG-00215-Cor-ahm ++ TAG-00043-Goo-tek  +
D
DEU Gemeinsame Empfehlungen - zur Anzeige von Anwendungsbeobachtungen und nichtinterventionellen Unbedenklichkeits-studien 15-Dec-2022 2.7.3 +
TAG-00144-Qua-gew ++ TAG-00010-Non-Stu ++ TAG-00305-Sta-Sta ++ TAG-00340-Req-nfo  +
DEU DGEPi - GEP Guter Epidemiologischer Praxis Sep-2018 Leitlinie 6 6.5 - 6.7 +
TAG-00144-Qua-gew ++ TAG-00142-Mul-ent ++ TAG-00010-Non-Stu ++ TAG-00147-Ser-inD  +
DEU DGEPi - GEP Guter Epidemiologischer Praxis Sep-2018 Leitlinie 6 6.1 +
TAG-00144-Qua-gew ++ TAG-00340-Req-nfo ++ TAG-00338-Met-odi  +
I
ICH ICH E6 Guideline R3 (2025) III. Annex 1 2.11 +
TAG-00145-Ran-ute ++ TAG-00099-Ran-ndl ++ TAG-00314-Unb-ung ++ TAG-00246-Inv-hte ++ TAG-00123-Bli-ppe  +
U
USA 21 CFR Part 314 09-Apr-2025 § 314.126 (4) - (5) +
TAG-00145-Ran-ute ++ TAG-00123-Bli-ppe ++ TAG-00338-Met-odi ++ TAG-00320-Foo-eri  +
W
WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 9.2 +
TAG-00145-Ran-ute ++ TAG-00123-Bli-ppe ++ TAG-00099-Ran-ndl ++ TAG-00343-Doc-ten  +
Retrieved from "https://gxplex.org/index.php?title=Property:RefTags&oldid=20452"